Literature DB >> 3159485

OKB7, a monoclonal antibody that reacts at or near the C3d binding site of human CR2.

P E Rao, S D Wright, E F Westberg, G Goldstein.   

Abstract

OKB7, an IgG2 mouse monoclonal antibody, binds to the C3d receptor (CR2) of human B lymphocytes in or near the active site of the receptor. OKB7 precipitates the same molecule as monoclonal antibodies B2 and HB-5 which have previously been reported to react with the C3d receptor at epitopes distant from the active site. The epitope recognized by OKB7 is distinct from those bound by B2 and HB-5 as shown in competitive binding experiments and is near the complement binding site since OKB7 blocks EAC3d rosetting at concentrations as low as 1 microgram/ml in the absence of cross-linking antibodies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159485     DOI: 10.1016/0008-8749(85)90159-5

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

1.  The role of receptors for complement in the induction of polyclonal B-cell proliferation and differentiation.

Authors:  T F Tedder; J J Weis; L T Clement; D T Fearon; M D Cooper
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

2.  The complement fragment C3d facilitates phagocytosis by monocytes.

Authors:  T A Gaither; I Vargas; S Inada; M M Frank
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

3.  Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2.

Authors:  Daniel Ricklin; Salome K Ricklin-Lichtsteiner; Maciej M Markiewski; Brian V Geisbrecht; John D Lambris
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

Review 4.  Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.

Authors:  W M Prodinger
Journal:  Immunol Res       Date:  1999       Impact factor: 4.505

5.  Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2.

Authors:  C A Lowell; L B Klickstein; R H Carter; J A Mitchell; D T Fearon; J M Ahearn
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

6.  Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.

Authors:  D R Martin; A Yuryev; K R Kalli; D T Fearon; J M Ahearn
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.